로딩 중…
StockDiggingStockDigging

Danaher Corporation

DHR· NYSE
$197.51+1.30%
2026-08-03

Financials

Valuation Metrics

Danaher Corporation's Market Cap is $139.80B. At end of 2025 it was $162.05B. Ranked #112 of 3,111 in US market (top 4%), #72 of 1,666 on NYSE (top 4%), #4 of 206 in Health Care Equipment & Services (top 2%) by Market Cap.

Investment Metrics(as of 2026-08-03)

MetricValue
Size
Market Cap$139.80B
Revenue$25.11B
Net Income$4.00B
Total Assets$92.37B
Net Assets$52.58B
Employees58,000
Value
P/E34.91x
P/B2.66x
PEG0.62x
P/S5.57x
EV/EBITDA25.18x
FCF Yield3.91%
Profitability
ROE7.61%
ROA4.33%
Op. Margin20.42%
Revenue Growth5.54%
Earnings Growth56.76%
Financial Health
Debt Ratio75.67%
Total Debt$26.56B
FCF$5.47B
Cash$4.35B
Current Ratio1.65x
Net Debt/EBITDA3.45x
Dividend
Div. Yield0.69%
Div. Growth18.15%
Performance
1Y Return0.53%
1M Return-0.21%
From 52W High-18.65%
1Y MDD-33.11%
Trading
Volume2,368,366 shares
Trading Value$468M
Per Share
EPS$5.11
BPS$74.27

Company Info

CEO Mr. Rainer M. Blair
Employees 58,000
HQ Washington, United States

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.